Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,1580293,elimination half-life,The elimination half-life of serum aluminum after therapeutic dosing of sucralfate was 13.1 +/- 3.1 days.,Aluminum absorption and excretion following sucralfate therapy in chronic renal insufficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1580293/),d,13.1,9259,DB00364,Sucralfate
,25233871,AUC,"The area under the curve (AUC) and maximum plasma concentration (CMAX ) were significantly lower (P < 0.001) in the concurrent sucralfate suspension group (AUC 7.2 h·μg/mL, CMAX 0.43 μg/mL) than with doxycycline alone (AUC 36.0 h·μg/mL, CMAX 2.53 μg/mL) resulting in a relative bioavailability of 20%.",The effect of sucralfate tablets vs. suspension on oral doxycycline absorption in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25233871/),[h·μg] / [ml],7.2,36474,DB00364,Sucralfate
,25233871,AUC,"The area under the curve (AUC) and maximum plasma concentration (CMAX ) were significantly lower (P < 0.001) in the concurrent sucralfate suspension group (AUC 7.2 h·μg/mL, CMAX 0.43 μg/mL) than with doxycycline alone (AUC 36.0 h·μg/mL, CMAX 2.53 μg/mL) resulting in a relative bioavailability of 20%.",The effect of sucralfate tablets vs. suspension on oral doxycycline absorption in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25233871/),[h·μg] / [ml],36.0,36475,DB00364,Sucralfate
,25233871,relative bioavailability,"The area under the curve (AUC) and maximum plasma concentration (CMAX ) were significantly lower (P < 0.001) in the concurrent sucralfate suspension group (AUC 7.2 h·μg/mL, CMAX 0.43 μg/mL) than with doxycycline alone (AUC 36.0 h·μg/mL, CMAX 2.53 μg/mL) resulting in a relative bioavailability of 20%.",The effect of sucralfate tablets vs. suspension on oral doxycycline absorption in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25233871/),%,20,36476,DB00364,Sucralfate
,25233871,relative bioavailability,Delaying sucralfate suspension by 2 h after doxycycline administration resulted in no difference in doxycycline absorption as compared with doxycycline administration alone with a relative bioavailability of 74%.,The effect of sucralfate tablets vs. suspension on oral doxycycline absorption in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25233871/),%,74,36477,DB00364,Sucralfate
,26651022,AUC,Drug exposure of ciprofloxacin was highly variable (AUC 5.52-22.47 h μg/mL) compared to enrofloxacin (AUC 3.86-7.50 h μg/mL).,Effect of Sucralfate on the Relative Bioavailability of Enrofloxacin and Ciprofloxacin in Healthy Fed Dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26651022/),[h·μg] / [ml],5.52-22.47,38212,DB00364,Sucralfate
,26651022,AUC,Drug exposure of ciprofloxacin was highly variable (AUC 5.52-22.47 h μg/mL) compared to enrofloxacin (AUC 3.86-7.50 h μg/mL).,Effect of Sucralfate on the Relative Bioavailability of Enrofloxacin and Ciprofloxacin in Healthy Fed Dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26651022/),[h·μg] / [ml],3.86-7.50,38213,DB00364,Sucralfate
,26651022,relative bioavailability,The mean relative bioavailability for ciprofloxacin and concurrent sucralfate was 48% (range 8-143%) compared to ciprofloxacin alone.,Effect of Sucralfate on the Relative Bioavailability of Enrofloxacin and Ciprofloxacin in Healthy Fed Dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26651022/),%,48,38214,DB00364,Sucralfate
,26651022,Relative bioavailability,Relative bioavailability of ciprofloxacin improved to 87% (range 37-333%) when sucralfate was delayed by 2 hours.,Effect of Sucralfate on the Relative Bioavailability of Enrofloxacin and Ciprofloxacin in Healthy Fed Dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26651022/),%,87,38215,DB00364,Sucralfate
,26651022,relative bioavailability,"By contrast, relative bioavailability for enrofloxacin and concurrent sucralfate was 104% (94-115%).",Effect of Sucralfate on the Relative Bioavailability of Enrofloxacin and Ciprofloxacin in Healthy Fed Dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26651022/),%,104,38216,DB00364,Sucralfate
,12604553,maximum concentration of the drug in plasma (C(max)),"Data for 150 mg of ABT-773 were as follows: the maximum concentration of the drug in plasma (C(max)) was 318 ng/ml, its half-life was 5.66 h, and its area under the plasma concentration-time curve from 0 h to infinity (AUC(0- infinity )) was 1,662 ng.",ABT-773: pharmacokinetics and interactions with ranitidine and sucralfate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12604553/),[ng] / [ml],318,68403,DB00364,Sucralfate
,12604553,half-life,"Data for 150 mg of ABT-773 were as follows: the maximum concentration of the drug in plasma (C(max)) was 318 ng/ml, its half-life was 5.66 h, and its area under the plasma concentration-time curve from 0 h to infinity (AUC(0- infinity )) was 1,662 ng.",ABT-773: pharmacokinetics and interactions with ranitidine and sucralfate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12604553/),h,5.66,68404,DB00364,Sucralfate
,12604553,area under the plasma concentration-time curve from 0 h to infinity (AUC(0- infinity )),"Data for 150 mg of ABT-773 were as follows: the maximum concentration of the drug in plasma (C(max)) was 318 ng/ml, its half-life was 5.66 h, and its area under the plasma concentration-time curve from 0 h to infinity (AUC(0- infinity )) was 1,662 ng.",ABT-773: pharmacokinetics and interactions with ranitidine and sucralfate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12604553/),ng,"1,662",68405,DB00364,Sucralfate
,24611544,maximum plasma concentration (CMAX ),"The maximum plasma concentration (CMAX ) and area under the curve (AUC) of minocycline were 1.15 μg/mL and 8.0 h* μg/mL, respectively.",Effect of sucralfate on oral minocycline absorption in healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24611544/),[μg] / [ml],1.15,75760,DB00364,Sucralfate
,24611544,area under the curve (AUC),"The maximum plasma concentration (CMAX ) and area under the curve (AUC) of minocycline were 1.15 μg/mL and 8.0 h* μg/mL, respectively.",Effect of sucralfate on oral minocycline absorption in healthy dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24611544/),[h·μg] / [ml],8.0,75761,DB00364,Sucralfate
,24611544,CMAX,"The CMAX and AUC were significantly lower (P < 0.05) in the MS group (CMAX = 0.33 μg/mL, AUC 3.0 h*μg/mL) compared with M or MS+2 (CMAX = 0.97 μg/mL, AUC 10.3 h*μg/mL).",Effect of sucralfate on oral minocycline absorption in healthy dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24611544/),[μg] / [ml],0.33,75762,DB00364,Sucralfate
,24611544,AUC,"The CMAX and AUC were significantly lower (P < 0.05) in the MS group (CMAX = 0.33 μg/mL, AUC 3.0 h*μg/mL) compared with M or MS+2 (CMAX = 0.97 μg/mL, AUC 10.3 h*μg/mL).",Effect of sucralfate on oral minocycline absorption in healthy dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24611544/),[h·μg] / [ml],3.0,75763,DB00364,Sucralfate
,24611544,CMAX,"The CMAX and AUC were significantly lower (P < 0.05) in the MS group (CMAX = 0.33 μg/mL, AUC 3.0 h*μg/mL) compared with M or MS+2 (CMAX = 0.97 μg/mL, AUC 10.3 h*μg/mL).",Effect of sucralfate on oral minocycline absorption in healthy dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24611544/),[μg] / [ml],0.97,75764,DB00364,Sucralfate
,24611544,AUC,"The CMAX and AUC were significantly lower (P < 0.05) in the MS group (CMAX = 0.33 μg/mL, AUC 3.0 h*μg/mL) compared with M or MS+2 (CMAX = 0.97 μg/mL, AUC 10.3 h*μg/mL).",Effect of sucralfate on oral minocycline absorption in healthy dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24611544/),[h·μg] / [ml],10.3,75765,DB00364,Sucralfate
,24611544,minimum inhibitory concentration (MIC),A dose of 7.5 mg/kg p.o. q12 h achieves the pharmacodynamic index for a bacterial minimum inhibitory concentration (MIC) of 0.25 μg/mL (AUC:MIC≥33.9).,Effect of sucralfate on oral minocycline absorption in healthy dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24611544/),[μg] / [ml],0.25,75766,DB00364,Sucralfate
≥,24611544,AUC:MIC,A dose of 7.5 mg/kg p.o. q12 h achieves the pharmacodynamic index for a bacterial minimum inhibitory concentration (MIC) of 0.25 μg/mL (AUC:MIC≥33.9).,Effect of sucralfate on oral minocycline absorption in healthy dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24611544/),,33.9,75767,DB00364,Sucralfate
,11165820,T50,"Initial gastric emptying was similar (Mean T50+/-S.E.M.: cholestyramine=66.93+/-9.39 min; Carbopol=56.57+/-11.96 min; sucralfate=48.33+/-11.07 min; P=0.548: n=10), however, the emptying of cholestyramine slowed beyond 2 h.","Comparative scintigraphic assessment of the intragastric distribution and residence of cholestyramine, Carbopol 934P and sucralfate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11165820/),min,66.93,84012,DB00364,Sucralfate
,11165820,T50,"Initial gastric emptying was similar (Mean T50+/-S.E.M.: cholestyramine=66.93+/-9.39 min; Carbopol=56.57+/-11.96 min; sucralfate=48.33+/-11.07 min; P=0.548: n=10), however, the emptying of cholestyramine slowed beyond 2 h.","Comparative scintigraphic assessment of the intragastric distribution and residence of cholestyramine, Carbopol 934P and sucralfate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11165820/),min,56.57,84013,DB00364,Sucralfate
,11165820,T50,"Initial gastric emptying was similar (Mean T50+/-S.E.M.: cholestyramine=66.93+/-9.39 min; Carbopol=56.57+/-11.96 min; sucralfate=48.33+/-11.07 min; P=0.548: n=10), however, the emptying of cholestyramine slowed beyond 2 h.","Comparative scintigraphic assessment of the intragastric distribution and residence of cholestyramine, Carbopol 934P and sucralfate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11165820/),min,48.33,84014,DB00364,Sucralfate
,11165820,AUC0-6,"This resulted in greater residence for cholestyramine (Mean AUC0-6+/-S.E.M. (relative units)=11516+/-686 versus 7657+/-1170 versus 6170+/-998; cholestyramine versus Carbopol versus sucralfate; P=0.004: n=10), with approximately 25% remaining in the stomach at 6 h compared to 3.84 and 2.65% of Carbopol and sucralfate, respectively.","Comparative scintigraphic assessment of the intragastric distribution and residence of cholestyramine, Carbopol 934P and sucralfate. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11165820/),,11516,84015,DB00364,Sucralfate
,11165820,AUC0-6,"This resulted in greater residence for cholestyramine (Mean AUC0-6+/-S.E.M. (relative units)=11516+/-686 versus 7657+/-1170 versus 6170+/-998; cholestyramine versus Carbopol versus sucralfate; P=0.004: n=10), with approximately 25% remaining in the stomach at 6 h compared to 3.84 and 2.65% of Carbopol and sucralfate, respectively.","Comparative scintigraphic assessment of the intragastric distribution and residence of cholestyramine, Carbopol 934P and sucralfate. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11165820/),,7657,84016,DB00364,Sucralfate
,11165820,AUC0-6,"This resulted in greater residence for cholestyramine (Mean AUC0-6+/-S.E.M. (relative units)=11516+/-686 versus 7657+/-1170 versus 6170+/-998; cholestyramine versus Carbopol versus sucralfate; P=0.004: n=10), with approximately 25% remaining in the stomach at 6 h compared to 3.84 and 2.65% of Carbopol and sucralfate, respectively.","Comparative scintigraphic assessment of the intragastric distribution and residence of cholestyramine, Carbopol 934P and sucralfate. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11165820/),,6170,84017,DB00364,Sucralfate
,33107158,oral bioavailability,"Rivaroxaban is a new anticoagulant option for dogs, yet its reported oral bioavailability is as low as 60%.",The influence of feeding and gastroprotectant medications on the Factor Xa inhibitory activity of orally administered rivaroxaban in normal dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33107158/),%,60,95797,DB00364,Sucralfate
,2735334,maximal plasma concentration,"In the presence of food, maximal plasma concentration decreased from 10.7 to 6.3 micrograms/ml after single-dose administration and 12.1 to 8.0 micrograms/ml after multiple-dose administration.",Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735334/),[μg] / [ml],10.7 to 6.3,121101,DB00364,Sucralfate
,2735334,maximal plasma concentration,"In the presence of food, maximal plasma concentration decreased from 10.7 to 6.3 micrograms/ml after single-dose administration and 12.1 to 8.0 micrograms/ml after multiple-dose administration.",Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735334/),[μg] / [ml],12.1 to 8.0,121102,DB00364,Sucralfate
,2735334,time to reach maximal plasma concentration,"The time to reach maximal plasma concentration was also modified by food, increasing from 2.8 to 7.1 hours after single-dose and 2.8 to 7.6 hours after multiple-dose administration.",Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735334/),h,2.8,121103,DB00364,Sucralfate
,2735334,time to reach maximal plasma concentration,"The time to reach maximal plasma concentration was also modified by food, increasing from 2.8 to 7.1 hours after single-dose and 2.8 to 7.6 hours after multiple-dose administration.",Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735334/),h,7,121104,DB00364,Sucralfate
,2735334,time to reach maximal plasma concentration,"The time to reach maximal plasma concentration was also modified by food, increasing from 2.8 to 7.1 hours after single-dose and 2.8 to 7.6 hours after multiple-dose administration.",Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735334/),h,2.8 to 7.6,121105,DB00364,Sucralfate
over,2735334,bioavailability,Food caused a significant decrease in the bioavailability of ketoprofen (over 40 percent) following both single-dose (23.8 versus 13.1 micrograms.hour/ml) and multiple-dose (29.3 versus 16.8 micrograms.hour/ml) administration.,Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735334/),%,40,121106,DB00364,Sucralfate
,2735334,bioavailability,Food caused a significant decrease in the bioavailability of ketoprofen (over 40 percent) following both single-dose (23.8 versus 13.1 micrograms.hour/ml) and multiple-dose (29.3 versus 16.8 micrograms.hour/ml) administration.,Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735334/),μ,23.8,121107,DB00364,Sucralfate
,2735334,bioavailability,Food caused a significant decrease in the bioavailability of ketoprofen (over 40 percent) following both single-dose (23.8 versus 13.1 micrograms.hour/ml) and multiple-dose (29.3 versus 16.8 micrograms.hour/ml) administration.,Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735334/),μ,13.1,121108,DB00364,Sucralfate
,2735334,bioavailability,Food caused a significant decrease in the bioavailability of ketoprofen (over 40 percent) following both single-dose (23.8 versus 13.1 micrograms.hour/ml) and multiple-dose (29.3 versus 16.8 micrograms.hour/ml) administration.,Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735334/),μ,29.3,121109,DB00364,Sucralfate
,2735334,bioavailability,Food caused a significant decrease in the bioavailability of ketoprofen (over 40 percent) following both single-dose (23.8 versus 13.1 micrograms.hour/ml) and multiple-dose (29.3 versus 16.8 micrograms.hour/ml) administration.,Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735334/),μ,16.8,121110,DB00364,Sucralfate
,2735334,absorption rate constant,"Results obtained in group 3 showed that sucralfate reduced the absorption rate constant of naproxen, from 1.7 to 1.2 hours-1 and from 1.5 to 0.7 hour-1 following single- and multiple-dose administration, respectively.",Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735334/),1/[h],1.7 to 1.2,121111,DB00364,Sucralfate
,2735334,absorption rate constant,"Results obtained in group 3 showed that sucralfate reduced the absorption rate constant of naproxen, from 1.7 to 1.2 hours-1 and from 1.5 to 0.7 hour-1 following single- and multiple-dose administration, respectively.",Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735334/),1/[h],1.5 to 0.7,121112,DB00364,Sucralfate
,11352442,area under the concentration-time curve from zero to infinity (AUCinfinity),"The concomitant administration of Al3+ reduced the bioavailability of moxifloxacin [geometric mean area under the concentration-time curve from zero to infinity (AUCinfinity) 12.9 versus 32.2 mg/L x h; relative bioavailability 40%, 90% confidence interval (CI) 33 to 49%] and slowed down the absorption rate [median time to maximum concentration (tmax) 3.5 versus 1.0 hours], with a reduction of the maximum plasma concentration (Cmax) fgeometric mean Cmax0.82 versus 2.83 mg/L; estimated true ratio of Cmax 29%, 90% CI 20 to 42%].","Effects of sucralfate on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352442/),[mg] / [h·l],12.9,131625,DB00364,Sucralfate
,11352442,area under the concentration-time curve from zero to infinity (AUCinfinity),"The concomitant administration of Al3+ reduced the bioavailability of moxifloxacin [geometric mean area under the concentration-time curve from zero to infinity (AUCinfinity) 12.9 versus 32.2 mg/L x h; relative bioavailability 40%, 90% confidence interval (CI) 33 to 49%] and slowed down the absorption rate [median time to maximum concentration (tmax) 3.5 versus 1.0 hours], with a reduction of the maximum plasma concentration (Cmax) fgeometric mean Cmax0.82 versus 2.83 mg/L; estimated true ratio of Cmax 29%, 90% CI 20 to 42%].","Effects of sucralfate on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352442/),[mg] / [h·l],32.2,131626,DB00364,Sucralfate
,11352442,relative bioavailability,"The concomitant administration of Al3+ reduced the bioavailability of moxifloxacin [geometric mean area under the concentration-time curve from zero to infinity (AUCinfinity) 12.9 versus 32.2 mg/L x h; relative bioavailability 40%, 90% confidence interval (CI) 33 to 49%] and slowed down the absorption rate [median time to maximum concentration (tmax) 3.5 versus 1.0 hours], with a reduction of the maximum plasma concentration (Cmax) fgeometric mean Cmax0.82 versus 2.83 mg/L; estimated true ratio of Cmax 29%, 90% CI 20 to 42%].","Effects of sucralfate on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352442/),%,40,131627,DB00364,Sucralfate
,11352442,time to maximum concentration (tmax),"The concomitant administration of Al3+ reduced the bioavailability of moxifloxacin [geometric mean area under the concentration-time curve from zero to infinity (AUCinfinity) 12.9 versus 32.2 mg/L x h; relative bioavailability 40%, 90% confidence interval (CI) 33 to 49%] and slowed down the absorption rate [median time to maximum concentration (tmax) 3.5 versus 1.0 hours], with a reduction of the maximum plasma concentration (Cmax) fgeometric mean Cmax0.82 versus 2.83 mg/L; estimated true ratio of Cmax 29%, 90% CI 20 to 42%].","Effects of sucralfate on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352442/),h,3.5,131628,DB00364,Sucralfate
,11352442,time to maximum concentration (tmax),"The concomitant administration of Al3+ reduced the bioavailability of moxifloxacin [geometric mean area under the concentration-time curve from zero to infinity (AUCinfinity) 12.9 versus 32.2 mg/L x h; relative bioavailability 40%, 90% confidence interval (CI) 33 to 49%] and slowed down the absorption rate [median time to maximum concentration (tmax) 3.5 versus 1.0 hours], with a reduction of the maximum plasma concentration (Cmax) fgeometric mean Cmax0.82 versus 2.83 mg/L; estimated true ratio of Cmax 29%, 90% CI 20 to 42%].","Effects of sucralfate on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11352442/),h,1.0,131629,DB00364,Sucralfate
,8489569,peak plasma concentration,After administration of a diclofenac-sucralfate association diclofenac was quickly absorbed and the peak plasma concentration (0.773 +/- 0.08 microgram/ml) was achieved in about 1 h.,Pharmacokinetic studies in healthy volunteers on a new gastroprotective pharmaceutic form of diclofenac. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489569/),[μg] / [ml],0.773,133557,DB00364,Sucralfate
,8489569,AUC(0-infinity),AUC(0-infinity) value was about 1.8 micrograms/ml/h and the mean elimination half-life was 1.20 +/- 0.12 h.,Pharmacokinetic studies in healthy volunteers on a new gastroprotective pharmaceutic form of diclofenac. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489569/),[μg] / [h·ml],1.8,133558,DB00364,Sucralfate
,8489569,elimination half-life,AUC(0-infinity) value was about 1.8 micrograms/ml/h and the mean elimination half-life was 1.20 +/- 0.12 h.,Pharmacokinetic studies in healthy volunteers on a new gastroprotective pharmaceutic form of diclofenac. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489569/),h,1.20,133559,DB00364,Sucralfate
,2712548,relative bioavailabilities,The relative bioavailabilities were 1.8% when norfloxacin was taken with sucralfate and 56.6% when it was taken 2 h after sucralfate.,Sucralfate reduces the gastrointestinal absorption of norfloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2712548/),%,1.8,150390,DB00364,Sucralfate
,2712548,relative bioavailabilities,The relative bioavailabilities were 1.8% when norfloxacin was taken with sucralfate and 56.6% when it was taken 2 h after sucralfate.,Sucralfate reduces the gastrointestinal absorption of norfloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2712548/),%,56.6,150391,DB00364,Sucralfate
,2712548,concentrations,"After norfloxacin was given alone, the mean norfloxacin concentrations in urine collected during intervals of 0 to 12, 12 to 24, and 24 to 28 h were 118.9 +/- 72.3, 18.8 +/- 12.5, and 2.4 +/- 2.2 micrograms/ml, respectively.",Sucralfate reduces the gastrointestinal absorption of norfloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2712548/),,18.8,150392,DB00364,Sucralfate
,2712548,concentrations,"After norfloxacin was given alone, the mean norfloxacin concentrations in urine collected during intervals of 0 to 12, 12 to 24, and 24 to 28 h were 118.9 +/- 72.3, 18.8 +/- 12.5, and 2.4 +/- 2.2 micrograms/ml, respectively.",Sucralfate reduces the gastrointestinal absorption of norfloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2712548/),,2.4,150393,DB00364,Sucralfate
,2712548,concentrations,"After norfloxacin was given with sucralfate, however, the mean norfloxacin concentrations in urine collected during the same time intervals were 6.8 +/- 4.7, 1.8 +/- 1.4, and 0 +/- 0 microgram/ml, respectively.",Sucralfate reduces the gastrointestinal absorption of norfloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2712548/),,1.8,150394,DB00364,Sucralfate
,2712548,concentrations,"After norfloxacin was given with sucralfate, however, the mean norfloxacin concentrations in urine collected during the same time intervals were 6.8 +/- 4.7, 1.8 +/- 1.4, and 0 +/- 0 microgram/ml, respectively.",Sucralfate reduces the gastrointestinal absorption of norfloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2712548/),,0,150395,DB00364,Sucralfate
,12043956,AUC0-infinity,"The mean parameters, AUC0-infinity and Cmax, following rosiglitazone administration alone were 3825.02 ng x h/ml and 664.47 ng/ml, respectively, and for rosiglitazone administered after pretreatment with sucralfate were 4848.19 ng x h/ml and 624.88 ng/ml, respectively.",Lack of effect of sucralfate on the absorption and pharmacokinetics of rosiglitazone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12043956/),[h·ng] / [ml],3825.02,153833,DB00364,Sucralfate
,12043956,AUC0-infinity,"The mean parameters, AUC0-infinity and Cmax, following rosiglitazone administration alone were 3825.02 ng x h/ml and 664.47 ng/ml, respectively, and for rosiglitazone administered after pretreatment with sucralfate were 4848.19 ng x h/ml and 624.88 ng/ml, respectively.",Lack of effect of sucralfate on the absorption and pharmacokinetics of rosiglitazone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12043956/),[ng] / [ml],664.47,153834,DB00364,Sucralfate
,12043956,AUC0-infinity,"The mean parameters, AUC0-infinity and Cmax, following rosiglitazone administration alone were 3825.02 ng x h/ml and 664.47 ng/ml, respectively, and for rosiglitazone administered after pretreatment with sucralfate were 4848.19 ng x h/ml and 624.88 ng/ml, respectively.",Lack of effect of sucralfate on the absorption and pharmacokinetics of rosiglitazone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12043956/),[h·ng] / [ml],4848.19,153835,DB00364,Sucralfate
,12043956,Cmax,"The mean parameters, AUC0-infinity and Cmax, following rosiglitazone administration alone were 3825.02 ng x h/ml and 664.47 ng/ml, respectively, and for rosiglitazone administered after pretreatment with sucralfate were 4848.19 ng x h/ml and 624.88 ng/ml, respectively.",Lack of effect of sucralfate on the absorption and pharmacokinetics of rosiglitazone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12043956/),[ng] / [ml],664.47,153836,DB00364,Sucralfate
,12043956,Cmax,"The mean parameters, AUC0-infinity and Cmax, following rosiglitazone administration alone were 3825.02 ng x h/ml and 664.47 ng/ml, respectively, and for rosiglitazone administered after pretreatment with sucralfate were 4848.19 ng x h/ml and 624.88 ng/ml, respectively.",Lack of effect of sucralfate on the absorption and pharmacokinetics of rosiglitazone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12043956/),[ng] / [ml],624.88,153837,DB00364,Sucralfate
,12043956,t(max),"The t(max) for rosiglitazone alone and for rosiglitazone after sucralfate treatments was 1.11 and 1.67 hours, respectively.",Lack of effect of sucralfate on the absorption and pharmacokinetics of rosiglitazone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12043956/),h,1.11,153838,DB00364,Sucralfate
,12043956,t(max),"The t(max) for rosiglitazone alone and for rosiglitazone after sucralfate treatments was 1.11 and 1.67 hours, respectively.",Lack of effect of sucralfate on the absorption and pharmacokinetics of rosiglitazone. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12043956/),h,1.67,153839,DB00364,Sucralfate
,12043956,elimination half-life,"The mean elimination half-life for rosiglitazone and rosiglitazone after sucralfate treatment was 4.35 and 4.51 hours, respectively.",Lack of effect of sucralfate on the absorption and pharmacokinetics of rosiglitazone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12043956/),h,4.35,153840,DB00364,Sucralfate
,12043956,elimination half-life,"The mean elimination half-life for rosiglitazone and rosiglitazone after sucralfate treatment was 4.35 and 4.51 hours, respectively.",Lack of effect of sucralfate on the absorption and pharmacokinetics of rosiglitazone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12043956/),h,4.51,153841,DB00364,Sucralfate
,2037712,area under the curve,"The mean (+/- SD) area under the curve was 2668 (729) mg - hr/L and 2748 (716) mg - hr/L for CMT and CMT/sucralfate treatments, respectively.",Influence of sucralfate on trilisate bioavailability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2037712/),[-·h·mg] / [l],2668,170066,DB00364,Sucralfate
,2037712,area under the curve,"The mean (+/- SD) area under the curve was 2668 (729) mg - hr/L and 2748 (716) mg - hr/L for CMT and CMT/sucralfate treatments, respectively.",Influence of sucralfate on trilisate bioavailability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2037712/),[-·h·mg] / [l],2748,170067,DB00364,Sucralfate
,2037712,maximum concentration,"Mean (+/- SD) maximum concentration was 275 (69) mg/L and 283 (75) mg/L for CMT and CMT/sucralfate administrations, respectively.",Influence of sucralfate on trilisate bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2037712/),[mg] / [l],275,170068,DB00364,Sucralfate
,2037712,maximum concentration,"Mean (+/- SD) maximum concentration was 275 (69) mg/L and 283 (75) mg/L for CMT and CMT/sucralfate administrations, respectively.",Influence of sucralfate on trilisate bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2037712/),[mg] / [l],283,170069,DB00364,Sucralfate
,2037712,time to maximum concentration,"Mean (+/- SD) time to maximum concentration for CMT and CMT/sucralfate treatments was 1.8 (0.6) hours and 1.7 (0.7) hours, respectively.",Influence of sucralfate on trilisate bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2037712/),h,1.8,170070,DB00364,Sucralfate
,2037712,time to maximum concentration,"Mean (+/- SD) time to maximum concentration for CMT and CMT/sucralfate treatments was 1.8 (0.6) hours and 1.7 (0.7) hours, respectively.",Influence of sucralfate on trilisate bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2037712/),h,1.7,170071,DB00364,Sucralfate
,7910724,area under the concentration-time curve,"Simultaneous administration of ketoconazole and sucralfate led to a significant reduction in the area under the concentration-time curve and maximal concentration of ketoconazole in serum (78.12 +/- 12.20 versus 59.32 +/- 13.61 micrograms.h/ml and 12.34 +/- 3.07 versus 8.92 +/- 2.57 micrograms/ml, respectively; P < 0.05).",In vivo interaction of ketoconazole and sucralfate in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910724/),[h·μg] / [ml],78.12,175099,DB00364,Sucralfate
,7910724,area under the concentration-time curve,"Simultaneous administration of ketoconazole and sucralfate led to a significant reduction in the area under the concentration-time curve and maximal concentration of ketoconazole in serum (78.12 +/- 12.20 versus 59.32 +/- 13.61 micrograms.h/ml and 12.34 +/- 3.07 versus 8.92 +/- 2.57 micrograms/ml, respectively; P < 0.05).",In vivo interaction of ketoconazole and sucralfate in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910724/),[h·μg] / [ml],59.32,175100,DB00364,Sucralfate
,7910724,maximal concentration,"Simultaneous administration of ketoconazole and sucralfate led to a significant reduction in the area under the concentration-time curve and maximal concentration of ketoconazole in serum (78.12 +/- 12.20 versus 59.32 +/- 13.61 micrograms.h/ml and 12.34 +/- 3.07 versus 8.92 +/- 2.57 micrograms/ml, respectively; P < 0.05).",In vivo interaction of ketoconazole and sucralfate in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910724/),[μg] / [ml],12.34,175101,DB00364,Sucralfate
,7910724,maximal concentration,"Simultaneous administration of ketoconazole and sucralfate led to a significant reduction in the area under the concentration-time curve and maximal concentration of ketoconazole in serum (78.12 +/- 12.20 versus 59.32 +/- 13.61 micrograms.h/ml and 12.34 +/- 3.07 versus 8.92 +/- 2.57 micrograms/ml, respectively; P < 0.05).",In vivo interaction of ketoconazole and sucralfate in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910724/),[μg] / [ml],8.92,175102,DB00364,Sucralfate
,9257738,maximum concentration of drug in serum (C(max)),"Pharmacokinetic parameters for sparfloxacin alone were as follows (mean +/- standard deviation): maximum concentration of drug in serum (C(max)), 1.27 +/- 0.39 microg/ml; time to C(max) (T(max)), 4.1 +/- 1.9 h; area under the concentration-time curve (AUC), 35.0 +/- 9.7 microg x h/ml; mean residence time, 28.5 +/- 5.7 h; half-life (t1/2), 20 +/- 4 h; urinary recovery (UR x f), 11.0% +/- 2.7%; and metabolite-sparfloxacin ratio in urine, 2.6.",Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257738/),[μg] / [ml],1.27,181234,DB00364,Sucralfate
,9257738,time to C(max) (T(max)),"Pharmacokinetic parameters for sparfloxacin alone were as follows (mean +/- standard deviation): maximum concentration of drug in serum (C(max)), 1.27 +/- 0.39 microg/ml; time to C(max) (T(max)), 4.1 +/- 1.9 h; area under the concentration-time curve (AUC), 35.0 +/- 9.7 microg x h/ml; mean residence time, 28.5 +/- 5.7 h; half-life (t1/2), 20 +/- 4 h; urinary recovery (UR x f), 11.0% +/- 2.7%; and metabolite-sparfloxacin ratio in urine, 2.6.",Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257738/),h,4.1,181235,DB00364,Sucralfate
,9257738,area under the concentration-time curve (AUC),"Pharmacokinetic parameters for sparfloxacin alone were as follows (mean +/- standard deviation): maximum concentration of drug in serum (C(max)), 1.27 +/- 0.39 microg/ml; time to C(max) (T(max)), 4.1 +/- 1.9 h; area under the concentration-time curve (AUC), 35.0 +/- 9.7 microg x h/ml; mean residence time, 28.5 +/- 5.7 h; half-life (t1/2), 20 +/- 4 h; urinary recovery (UR x f), 11.0% +/- 2.7%; and metabolite-sparfloxacin ratio in urine, 2.6.",Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257738/),[h·μg] / [ml],35.0,181236,DB00364,Sucralfate
,9257738,mean residence time,"Pharmacokinetic parameters for sparfloxacin alone were as follows (mean +/- standard deviation): maximum concentration of drug in serum (C(max)), 1.27 +/- 0.39 microg/ml; time to C(max) (T(max)), 4.1 +/- 1.9 h; area under the concentration-time curve (AUC), 35.0 +/- 9.7 microg x h/ml; mean residence time, 28.5 +/- 5.7 h; half-life (t1/2), 20 +/- 4 h; urinary recovery (UR x f), 11.0% +/- 2.7%; and metabolite-sparfloxacin ratio in urine, 2.6.",Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257738/),h,28.5,181237,DB00364,Sucralfate
,9257738,half-life (t1/2),"Pharmacokinetic parameters for sparfloxacin alone were as follows (mean +/- standard deviation): maximum concentration of drug in serum (C(max)), 1.27 +/- 0.39 microg/ml; time to C(max) (T(max)), 4.1 +/- 1.9 h; area under the concentration-time curve (AUC), 35.0 +/- 9.7 microg x h/ml; mean residence time, 28.5 +/- 5.7 h; half-life (t1/2), 20 +/- 4 h; urinary recovery (UR x f), 11.0% +/- 2.7%; and metabolite-sparfloxacin ratio in urine, 2.6.",Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257738/),h,20,181238,DB00364,Sucralfate
,9257738,urinary recovery (UR x f),"Pharmacokinetic parameters for sparfloxacin alone were as follows (mean +/- standard deviation): maximum concentration of drug in serum (C(max)), 1.27 +/- 0.39 microg/ml; time to C(max) (T(max)), 4.1 +/- 1.9 h; area under the concentration-time curve (AUC), 35.0 +/- 9.7 microg x h/ml; mean residence time, 28.5 +/- 5.7 h; half-life (t1/2), 20 +/- 4 h; urinary recovery (UR x f), 11.0% +/- 2.7%; and metabolite-sparfloxacin ratio in urine, 2.6.",Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257738/),%,11.0,181239,DB00364,Sucralfate
,9257738,ratio,"Pharmacokinetic parameters for sparfloxacin alone were as follows (mean +/- standard deviation): maximum concentration of drug in serum (C(max)), 1.27 +/- 0.39 microg/ml; time to C(max) (T(max)), 4.1 +/- 1.9 h; area under the concentration-time curve (AUC), 35.0 +/- 9.7 microg x h/ml; mean residence time, 28.5 +/- 5.7 h; half-life (t1/2), 20 +/- 4 h; urinary recovery (UR x f), 11.0% +/- 2.7%; and metabolite-sparfloxacin ratio in urine, 2.6.",Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257738/),,2.6,181240,DB00364,Sucralfate
,9257738,T(max),For the cisapride group there was a significant decrease in the sparfloxacin T(max) (1.9 +/- 2.1 h) and a significant increase in C(max) (1.74 +/- 0.73 microg/ml).,Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257738/),h,1.9,181241,DB00364,Sucralfate
,9257738,C(max),For the cisapride group there was a significant decrease in the sparfloxacin T(max) (1.9 +/- 2.1 h) and a significant increase in C(max) (1.74 +/- 0.73 microg/ml).,Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257738/),[μg] / [ml],1.74,181242,DB00364,Sucralfate
,9257738,C(max),"Significant differences in the values for the group receiving sucralfate compared to the values for the group receiving sparfloxacin alone were found: C(max), 0.77 +/- 0.31 microg/ml; AUC, 18.6 +/- 5.8 microg x h/ml; t1/2, 26 +/- 10 h; and UR x f, 5.8 +/- 1.8%.",Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257738/),[μg] / [ml],0.77,181243,DB00364,Sucralfate
,9257738,AUC,"Significant differences in the values for the group receiving sucralfate compared to the values for the group receiving sparfloxacin alone were found: C(max), 0.77 +/- 0.31 microg/ml; AUC, 18.6 +/- 5.8 microg x h/ml; t1/2, 26 +/- 10 h; and UR x f, 5.8 +/- 1.8%.",Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257738/),[h·μg] / [ml],18.6,181244,DB00364,Sucralfate
,9257738,t1/2,"Significant differences in the values for the group receiving sucralfate compared to the values for the group receiving sparfloxacin alone were found: C(max), 0.77 +/- 0.31 microg/ml; AUC, 18.6 +/- 5.8 microg x h/ml; t1/2, 26 +/- 10 h; and UR x f, 5.8 +/- 1.8%.",Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257738/),h,26,181245,DB00364,Sucralfate
,9257738,UR x f,"Significant differences in the values for the group receiving sucralfate compared to the values for the group receiving sparfloxacin alone were found: C(max), 0.77 +/- 0.31 microg/ml; AUC, 18.6 +/- 5.8 microg x h/ml; t1/2, 26 +/- 10 h; and UR x f, 5.8 +/- 1.8%.",Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9257738/),%,5.8,181246,DB00364,Sucralfate
,3413794,Systemic clearance,"Systemic clearance of Al was less in renally impaired rabbits (39 vs. 53 ml/hr/kg), as were the steady-state volume of distribution (516 vs. 1175 ml/kg), the half-life of elimination (14 vs. 27 hr), and the mean residence time of Al (14 vs. 25 hr).","Influence of renal impairment, chemical form, and serum protein binding on intravenous and oral aluminum kinetics in the rabbit. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3413794/),[ml] / [h·kg],39,188028,DB00364,Sucralfate
,3413794,Systemic clearance,"Systemic clearance of Al was less in renally impaired rabbits (39 vs. 53 ml/hr/kg), as were the steady-state volume of distribution (516 vs. 1175 ml/kg), the half-life of elimination (14 vs. 27 hr), and the mean residence time of Al (14 vs. 25 hr).","Influence of renal impairment, chemical form, and serum protein binding on intravenous and oral aluminum kinetics in the rabbit. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3413794/),[ml] / [h·kg],53,188029,DB00364,Sucralfate
,3413794,steady-state volume of distribution,"Systemic clearance of Al was less in renally impaired rabbits (39 vs. 53 ml/hr/kg), as were the steady-state volume of distribution (516 vs. 1175 ml/kg), the half-life of elimination (14 vs. 27 hr), and the mean residence time of Al (14 vs. 25 hr).","Influence of renal impairment, chemical form, and serum protein binding on intravenous and oral aluminum kinetics in the rabbit. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3413794/),[ml] / [kg],516,188030,DB00364,Sucralfate
,3413794,steady-state volume of distribution,"Systemic clearance of Al was less in renally impaired rabbits (39 vs. 53 ml/hr/kg), as were the steady-state volume of distribution (516 vs. 1175 ml/kg), the half-life of elimination (14 vs. 27 hr), and the mean residence time of Al (14 vs. 25 hr).","Influence of renal impairment, chemical form, and serum protein binding on intravenous and oral aluminum kinetics in the rabbit. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3413794/),[ml] / [kg],1175,188031,DB00364,Sucralfate
,3413794,half-life of elimination,"Systemic clearance of Al was less in renally impaired rabbits (39 vs. 53 ml/hr/kg), as were the steady-state volume of distribution (516 vs. 1175 ml/kg), the half-life of elimination (14 vs. 27 hr), and the mean residence time of Al (14 vs. 25 hr).","Influence of renal impairment, chemical form, and serum protein binding on intravenous and oral aluminum kinetics in the rabbit. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3413794/),h,14,188032,DB00364,Sucralfate
,3413794,half-life of elimination,"Systemic clearance of Al was less in renally impaired rabbits (39 vs. 53 ml/hr/kg), as were the steady-state volume of distribution (516 vs. 1175 ml/kg), the half-life of elimination (14 vs. 27 hr), and the mean residence time of Al (14 vs. 25 hr).","Influence of renal impairment, chemical form, and serum protein binding on intravenous and oral aluminum kinetics in the rabbit. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3413794/),h,27,188033,DB00364,Sucralfate
,3413794,mean residence time,"Systemic clearance of Al was less in renally impaired rabbits (39 vs. 53 ml/hr/kg), as were the steady-state volume of distribution (516 vs. 1175 ml/kg), the half-life of elimination (14 vs. 27 hr), and the mean residence time of Al (14 vs. 25 hr).","Influence of renal impairment, chemical form, and serum protein binding on intravenous and oral aluminum kinetics in the rabbit. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3413794/),h,14,188034,DB00364,Sucralfate
,3413794,mean residence time,"Systemic clearance of Al was less in renally impaired rabbits (39 vs. 53 ml/hr/kg), as were the steady-state volume of distribution (516 vs. 1175 ml/kg), the half-life of elimination (14 vs. 27 hr), and the mean residence time of Al (14 vs. 25 hr).","Influence of renal impairment, chemical form, and serum protein binding on intravenous and oral aluminum kinetics in the rabbit. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3413794/),h,25,188035,DB00364,Sucralfate
,3413794,Oral bioavailability,Oral bioavailability of Al in renally intact rabbits ranged from 0.3 to 2.2% (Al borate less than glycinate less than hydroxide less than chloride less than sucralfate less than lactate less than nitrate less than citrate).,"Influence of renal impairment, chemical form, and serum protein binding on intravenous and oral aluminum kinetics in the rabbit. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3413794/),%,0.3 to 2.2,188036,DB00364,Sucralfate
less,3413794,ultrafilterability,"In vitro and in vivo determination of Al ultrafilterability (less than 30,000 D) as an estimate of serum protein binding suggested a greater percentage of ultrafilterable Al species in renally impaired rabbit serum than in control rabbit serum.","Influence of renal impairment, chemical form, and serum protein binding on intravenous and oral aluminum kinetics in the rabbit. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3413794/),d,"30,000",188037,DB00364,Sucralfate
,3755676,AUC48,The phenytoin AUC48 was reduced from 173.6 +/- 22.6 mg .,Effect of sucralfate on phenytoin bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3755676/),mg,173.6,191442,DB00364,Sucralfate
,3755676,AUC120,"h/L to 157.1 +/- 19.6 mg . h/L (p less than 0.02), and the phenytoin AUC120 was reduced from 200.5 +/- 31.9 mg .",Effect of sucralfate on phenytoin bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3755676/),mg,200.5,191443,DB00364,Sucralfate
,1482143,relative bioavailability,"The relative bioavailability of fleroxacin given with sucralfate, calculated from the area under the concentration-time curve, was 76% compared with that of fleroxacin alone.",Effect of sucralfate on pharmacokinetics of fleroxacin in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1482143/),%,76,194657,DB00364,Sucralfate
,1482143,bioavailabilities,This is significantly better than the bioavailabilities of other quinolones (1.8 to 12.3%) when they are administered with sucralfate.,Effect of sucralfate on pharmacokinetics of fleroxacin in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1482143/),%,1.8 to 12.3,194658,DB00364,Sucralfate
,9056060,"AUC(0,8 h)","Pre-treatment with sucralfate significantly decreased both the AUC(0,8 h) [2265 ng h ml-1 (geometric mean) (range 1815-2827) vs 1821 ng h ml-1 (1295-2562)] and the Cmax [1135 ng ml-1 (geometric mean) (range 898-1436) 701 ng ml-1 (501-981)] with no significant delay in absorption [tmax 1.0 h (median) (range 0.5-2.0) vs 1.0 h (0.5-4.0)].",Short-term sucralfate administration alters potassium diclofenac absorption in healthy male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9056060/),[h·ng] / [ml],2265,201717,DB00364,Sucralfate
,9056060,"AUC(0,8 h)","Pre-treatment with sucralfate significantly decreased both the AUC(0,8 h) [2265 ng h ml-1 (geometric mean) (range 1815-2827) vs 1821 ng h ml-1 (1295-2562)] and the Cmax [1135 ng ml-1 (geometric mean) (range 898-1436) 701 ng ml-1 (501-981)] with no significant delay in absorption [tmax 1.0 h (median) (range 0.5-2.0) vs 1.0 h (0.5-4.0)].",Short-term sucralfate administration alters potassium diclofenac absorption in healthy male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9056060/),[h·ng] / [ml],1821,201718,DB00364,Sucralfate
,9056060,Cmax,"Pre-treatment with sucralfate significantly decreased both the AUC(0,8 h) [2265 ng h ml-1 (geometric mean) (range 1815-2827) vs 1821 ng h ml-1 (1295-2562)] and the Cmax [1135 ng ml-1 (geometric mean) (range 898-1436) 701 ng ml-1 (501-981)] with no significant delay in absorption [tmax 1.0 h (median) (range 0.5-2.0) vs 1.0 h (0.5-4.0)].",Short-term sucralfate administration alters potassium diclofenac absorption in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9056060/),[ng] / [ml],1135,201719,DB00364,Sucralfate
,9056060,Cmax,"Pre-treatment with sucralfate significantly decreased both the AUC(0,8 h) [2265 ng h ml-1 (geometric mean) (range 1815-2827) vs 1821 ng h ml-1 (1295-2562)] and the Cmax [1135 ng ml-1 (geometric mean) (range 898-1436) 701 ng ml-1 (501-981)] with no significant delay in absorption [tmax 1.0 h (median) (range 0.5-2.0) vs 1.0 h (0.5-4.0)].",Short-term sucralfate administration alters potassium diclofenac absorption in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9056060/),[ng] / [ml],70,201720,DB00364,Sucralfate
,9056060,tmax,"Pre-treatment with sucralfate significantly decreased both the AUC(0,8 h) [2265 ng h ml-1 (geometric mean) (range 1815-2827) vs 1821 ng h ml-1 (1295-2562)] and the Cmax [1135 ng ml-1 (geometric mean) (range 898-1436) 701 ng ml-1 (501-981)] with no significant delay in absorption [tmax 1.0 h (median) (range 0.5-2.0) vs 1.0 h (0.5-4.0)].",Short-term sucralfate administration alters potassium diclofenac absorption in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9056060/),h,1.0,201721,DB00364,Sucralfate
,9056060,tmax,"Pre-treatment with sucralfate significantly decreased both the AUC(0,8 h) [2265 ng h ml-1 (geometric mean) (range 1815-2827) vs 1821 ng h ml-1 (1295-2562)] and the Cmax [1135 ng ml-1 (geometric mean) (range 898-1436) 701 ng ml-1 (501-981)] with no significant delay in absorption [tmax 1.0 h (median) (range 0.5-2.0) vs 1.0 h (0.5-4.0)].",Short-term sucralfate administration alters potassium diclofenac absorption in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9056060/),h,1.0,201722,DB00364,Sucralfate
,10624593,fecal ciprofloxacin,"After more than 3 days of i.v. ciprofloxacin, the mean fecal ciprofloxacin concentration was 185.3 +/- 158.7 micrograms/g in patients of group A and 108.7 +/- 76.9 micrograms/g in patients without concurrent sucralfate (group B).",Elimination of fecal Enterobacteriaceae by intravenous ciprofloxacin is not inhibited by concomitant sucralfate--a microbiological and pharmacokinetic study in patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10624593/),[μg] / [g],185.,205017,DB00364,Sucralfate
,10624593,fecal ciprofloxacin,"After more than 3 days of i.v. ciprofloxacin, the mean fecal ciprofloxacin concentration was 185.3 +/- 158.7 micrograms/g in patients of group A and 108.7 +/- 76.9 micrograms/g in patients without concurrent sucralfate (group B).",Elimination of fecal Enterobacteriaceae by intravenous ciprofloxacin is not inhibited by concomitant sucralfate--a microbiological and pharmacokinetic study in patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10624593/),[μg] / [g],108.7,205018,DB00364,Sucralfate
,10624593,concentration,"After more than 3 days of i.v. ciprofloxacin, the mean fecal ciprofloxacin concentration was 185.3 +/- 158.7 micrograms/g in patients of group A and 108.7 +/- 76.9 micrograms/g in patients without concurrent sucralfate (group B).",Elimination of fecal Enterobacteriaceae by intravenous ciprofloxacin is not inhibited by concomitant sucralfate--a microbiological and pharmacokinetic study in patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10624593/),[μg] / [g],185.,205019,DB00364,Sucralfate
,10624593,concentration,"After more than 3 days of i.v. ciprofloxacin, the mean fecal ciprofloxacin concentration was 185.3 +/- 158.7 micrograms/g in patients of group A and 108.7 +/- 76.9 micrograms/g in patients without concurrent sucralfate (group B).",Elimination of fecal Enterobacteriaceae by intravenous ciprofloxacin is not inhibited by concomitant sucralfate--a microbiological and pharmacokinetic study in patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10624593/),[μg] / [g],108.7,205020,DB00364,Sucralfate
,27788591,peak concentration,"Chloroform was measured using headspace gas chromatograph mass spectrometry, with a peak concentration of 2.00 μg/mL, 4 h 20 min post-ingestion.","Chloroform ingestion causing severe gastrointestinal injury, hepatotoxicity and dermatitis confirmed with plasma chloroform concentrations. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27788591/),[μg] / [ml],2.00,212444,DB00364,Sucralfate
,27788591,elimination half-life,The concentration-time data fitted a 1-compartment model with elimination half-life 6.5 h.,"Chloroform ingestion causing severe gastrointestinal injury, hepatotoxicity and dermatitis confirmed with plasma chloroform concentrations. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27788591/),h,6.5,212445,DB00364,Sucralfate
,3799579,time of peak concentration,No significant differences were noted in any of the treatment phases for any of the parameters except for the time of peak concentration which was slightly delayed from 1.0 +/- 0.6 to 1.7 +/- 0.9 h when sucralfate was concomitantly administered with the prednisone.,Lack of effect of sucralfate on prednisone bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3799579/),h,1.0,241300,DB00364,Sucralfate
,3799579,time of peak concentration,No significant differences were noted in any of the treatment phases for any of the parameters except for the time of peak concentration which was slightly delayed from 1.0 +/- 0.6 to 1.7 +/- 0.9 h when sucralfate was concomitantly administered with the prednisone.,Lack of effect of sucralfate on prednisone bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3799579/),h,1.7,241301,DB00364,Sucralfate
,1781800,AUC (0-t),The AUC (0-t) was calculated at 1670 +/- 492 ng/ml x h for diclofenac alone and at 1817 +/- 682 ng/ml x h for diclofenac plus sucralfate.,Study on the interaction between sucralfate and diclofenac/piroxicam in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1781800/),[ng] / [h·ml],1670,245385,DB00364,Sucralfate
,1781800,AUC (0-t),The AUC (0-t) was calculated at 1670 +/- 492 ng/ml x h for diclofenac alone and at 1817 +/- 682 ng/ml x h for diclofenac plus sucralfate.,Study on the interaction between sucralfate and diclofenac/piroxicam in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1781800/),[ng] / [h·ml],1817,245386,DB00364,Sucralfate
,1781800,AUC (0-t),The mean AUC (0-t) for piroxicam alone was 91 +/- 19 micrograms/ml x h whilst that for piroxicam plus sucralfate was 91 +/- 20 micrograms/ml x h.,Study on the interaction between sucralfate and diclofenac/piroxicam in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1781800/),[μg] / [h·ml],91,245387,DB00364,Sucralfate
,1781800,AUC (0-t),The mean AUC (0-t) for piroxicam alone was 91 +/- 19 micrograms/ml x h whilst that for piroxicam plus sucralfate was 91 +/- 20 micrograms/ml x h.,Study on the interaction between sucralfate and diclofenac/piroxicam in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1781800/),[μg] / [h·ml],91,245388,DB00364,Sucralfate
,1781800,relative bioavailability,"The mean relative bioavailability was 116% for diclofenac plus sucralfate compared to diclofenac alone, and 100% for piroxicam plus sucralfate compared to piroxicam alone.",Study on the interaction between sucralfate and diclofenac/piroxicam in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1781800/),%,116,245389,DB00364,Sucralfate
,1781800,relative bioavailability,"The mean relative bioavailability was 116% for diclofenac plus sucralfate compared to diclofenac alone, and 100% for piroxicam plus sucralfate compared to piroxicam alone.",Study on the interaction between sucralfate and diclofenac/piroxicam in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1781800/),%,100,245390,DB00364,Sucralfate
,6896647,serum half-life,After i.v. injection in rats the 14C-radioactivity has a very short serum half-life of 1 h and is excreted almost completely by the kidneys.,"Sucralfate: pharmacokinetics, metabolism and selective binding to experimental gastric and duodenal ulcers in animals. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6896647/),h,1,249487,DB00364,Sucralfate
,32628058,AUC0-24,"After iv of levofloxacin, the mean (±SD) of AUC0-24, Vz, t½λz and MRT, was 19.05 ± 6.4 µg-h/ml, 2.43 ± 0.5 L/kg, 7.93 ± 1.41 hours and 8.7 ± 1.5 hours, respectively.","Pharmacokinetics of levofloxacin after single intravenous and oral administration, and its interaction with sucralfate in mixed-breed dogs. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32628058/),[µg-h] / [ml],19.05,260448,DB00364,Sucralfate
,32628058,Vz,"After iv of levofloxacin, the mean (±SD) of AUC0-24, Vz, t½λz and MRT, was 19.05 ± 6.4 µg-h/ml, 2.43 ± 0.5 L/kg, 7.93 ± 1.41 hours and 8.7 ± 1.5 hours, respectively.","Pharmacokinetics of levofloxacin after single intravenous and oral administration, and its interaction with sucralfate in mixed-breed dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32628058/),[l] / [kg],2.43,260449,DB00364,Sucralfate
,32628058,t½λz,"After iv of levofloxacin, the mean (±SD) of AUC0-24, Vz, t½λz and MRT, was 19.05 ± 6.4 µg-h/ml, 2.43 ± 0.5 L/kg, 7.93 ± 1.41 hours and 8.7 ± 1.5 hours, respectively.","Pharmacokinetics of levofloxacin after single intravenous and oral administration, and its interaction with sucralfate in mixed-breed dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32628058/),[l] / [kg],2.43,260450,DB00364,Sucralfate
,32628058,MRT,"After iv of levofloxacin, the mean (±SD) of AUC0-24, Vz, t½λz and MRT, was 19.05 ± 6.4 µg-h/ml, 2.43 ± 0.5 L/kg, 7.93 ± 1.41 hours and 8.7 ± 1.5 hours, respectively.","Pharmacokinetics of levofloxacin after single intravenous and oral administration, and its interaction with sucralfate in mixed-breed dogs. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32628058/),h,8.7,260451,DB00364,Sucralfate
,32628058,C max,"After oral administration, the C max, t½λz and bioavailability were 1.95 ± 0.7 µg/ml, 7.65 ± 1.38 hours and 71.93 ± 9.75%, respectively.","Pharmacokinetics of levofloxacin after single intravenous and oral administration, and its interaction with sucralfate in mixed-breed dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32628058/),[μg] / [ml],1.95,260452,DB00364,Sucralfate
,32628058,t½λz,"After oral administration, the C max, t½λz and bioavailability were 1.95 ± 0.7 µg/ml, 7.65 ± 1.38 hours and 71.93 ± 9.75%, respectively.","Pharmacokinetics of levofloxacin after single intravenous and oral administration, and its interaction with sucralfate in mixed-breed dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32628058/),h,7.65,260453,DB00364,Sucralfate
,32628058,bioavailability,"After oral administration, the C max, t½λz and bioavailability were 1.95 ± 0.7 µg/ml, 7.65 ± 1.38 hours and 71.93 ± 9.75%, respectively.","Pharmacokinetics of levofloxacin after single intravenous and oral administration, and its interaction with sucralfate in mixed-breed dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32628058/),%,71.93,260454,DB00364,Sucralfate
,32628058,C max,"In animals given an oral dose of levofloxacin with sucralfate pre-treatment, there was a significant decrease (p < 0.05) in C max (0.57 ± 0.23 µg/ml), AUC (5.73 ± 2.26 µg-h/ml) and bioavailability (31.92 ± 14.19%).","Pharmacokinetics of levofloxacin after single intravenous and oral administration, and its interaction with sucralfate in mixed-breed dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32628058/),[μg] / [ml],0.57,260455,DB00364,Sucralfate
,32628058,AUC,"In animals given an oral dose of levofloxacin with sucralfate pre-treatment, there was a significant decrease (p < 0.05) in C max (0.57 ± 0.23 µg/ml), AUC (5.73 ± 2.26 µg-h/ml) and bioavailability (31.92 ± 14.19%).","Pharmacokinetics of levofloxacin after single intravenous and oral administration, and its interaction with sucralfate in mixed-breed dogs. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32628058/),[µg-h] / [ml],5.73,260456,DB00364,Sucralfate
,32628058,bioavailability,"In animals given an oral dose of levofloxacin with sucralfate pre-treatment, there was a significant decrease (p < 0.05) in C max (0.57 ± 0.23 µg/ml), AUC (5.73 ± 2.26 µg-h/ml) and bioavailability (31.92 ± 14.19%).","Pharmacokinetics of levofloxacin after single intravenous and oral administration, and its interaction with sucralfate in mixed-breed dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32628058/),%,31.92,260457,DB00364,Sucralfate
,9333047,Tmax,"The only consistent effect of the coadministration of levofloxacin with a high-fat meal for most subjects was that levofloxacin absorption was delayed and Cmax was slightly reduced (Tmax, 1.0 and 2.0 h for fasting and fed conditions, respectively [P = 0.002]; Cmax, 5.9 +/- 1.3 and 5.1 +/- 0.9 microg/ml [90% confidence interval = 0.79 to 0.94] for fasting and fed conditions, respectively).",Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333047/),h,1.0,268569,DB00364,Sucralfate
,9333047,Tmax,"The only consistent effect of the coadministration of levofloxacin with a high-fat meal for most subjects was that levofloxacin absorption was delayed and Cmax was slightly reduced (Tmax, 1.0 and 2.0 h for fasting and fed conditions, respectively [P = 0.002]; Cmax, 5.9 +/- 1.3 and 5.1 +/- 0.9 microg/ml [90% confidence interval = 0.79 to 0.94] for fasting and fed conditions, respectively).",Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333047/),h,2.0,268570,DB00364,Sucralfate
,9333047,Cmax,"The only consistent effect of the coadministration of levofloxacin with a high-fat meal for most subjects was that levofloxacin absorption was delayed and Cmax was slightly reduced (Tmax, 1.0 and 2.0 h for fasting and fed conditions, respectively [P = 0.002]; Cmax, 5.9 +/- 1.3 and 5.1 +/- 0.9 microg/ml [90% confidence interval = 0.79 to 0.94] for fasting and fed conditions, respectively).",Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333047/),[μg] / [ml],5.9,268571,DB00364,Sucralfate
,9333047,Cmax,"The only consistent effect of the coadministration of levofloxacin with a high-fat meal for most subjects was that levofloxacin absorption was delayed and Cmax was slightly reduced (Tmax, 1.0 and 2.0 h for fasting and fed conditions, respectively [P = 0.002]; Cmax, 5.9 +/- 1.3 and 5.1 +/- 0.9 microg/ml [90% confidence interval = 0.79 to 0.94] for fasting and fed conditions, respectively).",Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333047/),[μg] / [ml],5.1,268572,DB00364,Sucralfate
,9333047,Cmax,"Mean values of Cmax and AUC from time zero to infinity were 6.7 +/- 3.2 microg/ml and 47.9 +/- 8.4 microg x h/ml, respectively, following the administration of sucralfate compared to values of 5.9 +/- 1.3 microg/ml and 50.5 +/- 8.1 microg x h/ml, respectively, under fasting conditions.",Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333047/),[μg] / [ml],6.7,268573,DB00364,Sucralfate
,9333047,Cmax,"Mean values of Cmax and AUC from time zero to infinity were 6.7 +/- 3.2 microg/ml and 47.9 +/- 8.4 microg x h/ml, respectively, following the administration of sucralfate compared to values of 5.9 +/- 1.3 microg/ml and 50.5 +/- 8.1 microg x h/ml, respectively, under fasting conditions.",Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333047/),[μg] / [ml],5.9,268574,DB00364,Sucralfate
,9333047,AUC from time zero to infinity,"Mean values of Cmax and AUC from time zero to infinity were 6.7 +/- 3.2 microg/ml and 47.9 +/- 8.4 microg x h/ml, respectively, following the administration of sucralfate compared to values of 5.9 +/- 1.3 microg/ml and 50.5 +/- 8.1 microg x h/ml, respectively, under fasting conditions.",Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333047/),[h·μg] / [ml],47.9,268575,DB00364,Sucralfate
,9333047,AUC from time zero to infinity,"Mean values of Cmax and AUC from time zero to infinity were 6.7 +/- 3.2 microg/ml and 47.9 +/- 8.4 microg x h/ml, respectively, following the administration of sucralfate compared to values of 5.9 +/- 1.3 microg/ml and 50.5 +/- 8.1 microg x h/ml, respectively, under fasting conditions.",Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333047/),[h·μg] / [ml],50.5,268576,DB00364,Sucralfate
,9068926,peak drug plasma concentration (Cmax),"Plasma concentrations in healthy volunteers reach a mean peak drug plasma concentration (Cmax) of approximately 2.8 and 5.2 mg/L within 1 to 2 hours after oral administration of levofloxacin 250 and 500mg tablets, respectively.",The clinical pharmacokinetics of levofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[mg] / [l],2.8,273446,DB00364,Sucralfate
,9068926,peak drug plasma concentration (Cmax),"Plasma concentrations in healthy volunteers reach a mean peak drug plasma concentration (Cmax) of approximately 2.8 and 5.2 mg/L within 1 to 2 hours after oral administration of levofloxacin 250 and 500mg tablets, respectively.",The clinical pharmacokinetics of levofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[mg] / [l],5.2,273447,DB00364,Sucralfate
,9068926,bioavailability,The bioavailability of oral levofloxacin approaches 100% and is little affected by the administration with food.,The clinical pharmacokinetics of levofloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),%,100,273448,DB00364,Sucralfate
,9068926,Cmax,"Single oral doses of levofloxacin 50 to 1000mg produce a mean Cmax and area under the concentration-time curve (AUC) ranging from approximately 0.6 to 9.4 mg/L and 4.7 to 108 mg.h/L, respectively, both increasing linearly in a dose-proportional fashion.",The clinical pharmacokinetics of levofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[mg] / [l],0.6 to 9.4,273449,DB00364,Sucralfate
,9068926,area under the concentration-time curve (AUC),"Single oral doses of levofloxacin 50 to 1000mg produce a mean Cmax and area under the concentration-time curve (AUC) ranging from approximately 0.6 to 9.4 mg/L and 4.7 to 108 mg.h/L, respectively, both increasing linearly in a dose-proportional fashion.",The clinical pharmacokinetics of levofloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[h·mg] / [l],4.7 to 108,273450,DB00364,Sucralfate
,9068926,volume of distribution,"Levofloxacin is widely distributed throughout the body, with a mean volume of distribution of 1.1 L/kg, and penetrates well into most body tissues and fluids.",The clinical pharmacokinetics of levofloxacin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[l] / [kg],1.1,273451,DB00364,Sucralfate
,9068926,plasma elimination half-life (t1/2 beta),The plasma elimination half-life (t1/2 beta) ranges from 6 to 8 hours in individuals with normal renal function.,The clinical pharmacokinetics of levofloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),h,6 to 8,273452,DB00364,Sucralfate
